American Renal Associates Holdings Inc. (NYSE:ARA) was down 4.8% during mid-day trading on Monday . The company traded as low as $22.66 and last traded at $22.70, with a volume of 131,681 shares. The stock had previously closed at $23.85.

A number of equities research analysts have recently issued reports on ARA shares. SunTrust Banks Inc. started coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They set a “buy” rating and a $34.00 price objective on the stock. Zacks Investment Research upgraded American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $29.00 price objective on the stock in a research note on Monday, July 18th. Goldman Sachs Group Inc. started coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They set a “neutral” rating and a $30.00 price objective on the stock. Leerink Swann reiterated an “outperform” rating on shares of American Renal Associates Holdings in a research note on Monday, May 16th. Finally, Wells Fargo & Co. started coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $31.80.

The firm has a market cap of $504.37 million and a price-to-earnings ratio of 11.56. The firm’s 50 day moving average price is $0.00 and its 200-day moving average price is $0.00.

American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings data on Thursday, May 12th. The company reported $0.16 EPS for the quarter. The business earned $172.10 million during the quarter, compared to the consensus estimate of $149.30 million. On average, equities analysts expect that American Renal Associates Holdings Inc. will post $0.88 earnings per share for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.